Bio Path reported $-270K in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Alterity Therapeutics Limited AUD -6.3M 525.41K Dec/2025
Baxter International USD 294M 168M Sep/2026
Bio Path USD -270K 706K Mar/2026
Cipla INR 8.78B 884.9M Sep/2026
Clal Biotechnology ILS -6.17M 15.56M Dec/2022
Compugen USD -7.01M 663K Jun/2026
CSL USD 401M 96.5M Dec/2025
Grifols EUR 114.37M 34.03M Dec/2025
Karyopharm Therapeutics USD -22.39M 79.81M Mar/2026